Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.20 +0.93%

+$0.14 today

Market cap
$3.37B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.76M

Average 1.21M

Income Statement

Follow revenue through to earnings.

Revenue

$0.00

FY 2025 · Annual

Operating Income

-$153.29M

FY 2025 · Annual

Net Income

-$144.74M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue022.23M380.79M87.37M0
Cost of Revenue02.99M25.44M42.16M525K
Gross Profit019.24M355.35M45.22M(525K)
Gross Margin—86.5%93.3%51.8%—
Research & Development44.04M93.45M128.19M104.08M90.4M
Selling, General & Admin38.93M127.13M188.36M114.33M62.89M
Operating Expenses82.69M220.58M316.54M359.95M152.77M
Depreciation & Amortization52K487K1.09M904K525K
EBITDA(87.88M)(197.11M)55.39M(290.98M)(144.16M)
EBITDA Margin—-886.7%14.5%-333.0%—
Operating Income(82.69M)(201.34M)38.8M(314.73M)(153.29M)
Operating Margin—-905.7%10.2%-360.2%—
Interest Income36K4.29M16.16M13.81M9.3M
Interest Expense00000
Other Income / Expenses(5.24M)3.74M15.5M12.6M8.6M
Income Before Tax(87.93M)(197.6M)54.3M(302.14M)(144.69M)
Pre-Tax Margin—-888.9%14.3%-345.8%—
Income Tax Expense0774K5.03M(393K)46K
Net Income(87.93M)(198.38M)49.27M(301.74M)(144.74M)
Net Margin—-892.4%12.9%-345.4%—
EPS (Basic)(1.52)(2.98)0.73(4.43)(1.53)
EPS (Diluted)(1.52)(2.98)0.70(4.43)(1.53)
Weighted Avg Shares57.86M66.51M67.23M68.14M94.57M
Weighted Avg Shares (Diluted)57.86M66.51M69.99M68.14M94.57M

AMLX Earnings Waterfall · TTM

NASDAQ:AMLX · Revenue to Net Income

Key Ratios

EPS$-1.42
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-12.7
P/S Ratio0.0

Analysis

$0 of revenue converted into -$163.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.42, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
4Statement of changes in beneficial ownershipNov 12, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026

How much revenue does AMLX generate?

Amylyx Pharmaceuticals, Inc. (AMLX) reported $0.00 of revenue in fiscal 2025.

Is AMLX profitable?

Amylyx Pharmaceuticals, Inc. (AMLX) reported -$144.74M of net income.